Medicare Benefits Schedule - Item 73337

Search Results for Item 73337

Category 6 - PATHOLOGY SERVICES

73337

73337 - Additional Information

Item Start Date:
01-Nov-2021
Description Updated:
01-Nov-2021
Schedule Fee Updated:
01-Jan-2014

Group
P7 - Genetics

A test of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine:

  1. if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to an EGFR tyrosine kinase inhibitor under the Pharmaceutical Benefits Scheme are fulfilled; or
  2. if the requirements relating to EGFR status for access to pembrolizumab under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $397.35 Benefit: 75% = $298.05 85% = $337.75


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change